Ascorbate in Myelodysplastic Syndrome

Study acronym: AIMS
StatusSuspended
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment suspended Sponsor's reason: temporary suspension
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 2 of 8 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2026 to Mar 11, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
Trial Details
NCT Number NCT07283900
Lead Sponsor Prajwal Dhakal
Conditions
(from sponsor)		 Myelodysplastic Syndromes
Related terms Myelodysplastic Syndromes
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov